Ultrafine Nanoparticles of Poly(Methyl Methacrylate-co-Methacrylic Acid) Loaded with Aspirin

R López-Muñoz,M E Treviño,R Díaz De León,J A Valdez-Garza,G Morales,F J Enríquez-Medrano,H Saade,R G López

doi:10.1155/2019/3059098

Abstract

Nanoparticles of the poly(methyl methacrylate-co-methacrylic acid) or copolymer of P(MMA-co-MAA), were prepared by semicontinuous heterophase polymerization; they show a mean diameter of 12 nm and a 1.75 MMA/MAA molar ratio determined by carbon-13 nuclear magnetic resonance. The content of MAA, greater than that of Eudragit S100, copolymer of P(MMA-co-MAA) accepted by the FDA for the preparation of tablets, ensures its biocompatibility and its metabolism without toxic effects. Loaded with up to 22 wt. % aspirin, that is, acetylsalicylic acid (ASA), these nanoparticles increase slightly their size, according to transmission electron microscopy; however, the presence of ASA on the nanoparticle surface decreases their stability, which leads to a certain aggregation of the particles in the dispersion. Fourier transform infrared spectrometry was used for demonstrating the loading of ASA in the nanoparticles.

Highlights

Biodegradable and biocompatible ultrafine nanoparticles are considered as ideal vehicles for drug delivery
Nanoparticles of the poly(methyl methacrylate-co-methacrylic acid) or copolymer of P(MMA-co-MAA), were prepared by semicontinuous heterophase polymerization; they show a mean diameter of 12 nm and a 1.75 MMA/MAA molar ratio determined by carbon-13 nuclear magnetic resonance
The number-average diameter (Dn) determined by Quasielastic Light Scattering (QLS) is 12 nm, which matches very well with that shown in the micrograph

Summary

Introduction

Biodegradable and biocompatible ultrafine nanoparticles are considered as ideal vehicles for drug delivery. In the case of antineoplastic-loaded nanostructures, at present, there are only less than 20 products in clinical use [7,8,9,10]. Among the main reasons behind the low number of drug-loaded nanostructures with FDA approval are those related to their characteristic size as well as the biocompatibility and biodegradability of the material that forms the nanostructures. Taking into account only the sizes, the nanostructures ranging from 10 to 100 nm in size would have the highest chances to remain in the bloodstream either to slowly release the drug or to reach the tumors, in the case of antineoplastic therapies. Considering that the smaller the size, the greater the probability of the nanostructures to evade the immunological system [13], sizes slightly greater than 10 nm are advisable for drugloaded nanostructures

Methods

Results

Conclusion